GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies


  • Zymework to receive preclinical, development & commercial milestone payments and royalties on WW sales. GSK to get an option to develop and commercialize bi-specific candidates for multiple indications including infectious diseases utilizing Zymeworks’ heavy-light chain pairing technology of Azymetric platform
  • In 2016, the companies collaborated to develop & commercialize up to six bispecific antibodies utilizing Zymeworks’s Azymetric platform
  • Zymeworks’s Azymetric platform allows the transformation of monospecific Ab to bispecific Ab, enabling it to bind with two different targets, thus reducing toxicities and drug resistance        

Click here to read full press release/ article | Ref: Business Wire | Image: The Hindu Business Line